1705749222
Older people often respond less well to therapy and are more likely to experience treatment-related side effects. A subgroup analysis of the randomized trial S1826 therefore investigated an alternative therapy option for patients with classic Hodgkin lymphoma aged 60 and over.
Wanlee/AdobeStock
This patient group is often faced with unique challenges, including existing comorbidities, impaired performance status, lower chemotherapy tolerance, and increased treatment-related toxicity. Those from Dr. Study led by Sarah Rutherford, S1826, compared the efficacy and safety of two first-line therapies, nivolumab-AVD (N-AVD) and brentuximab vedotin-AVD (Bv-AVD), in classical Hodgkin’s lymphoma. A subgroup analysis conducted examined whether any of these therapies improved the poorer survival rates observed in older individuals.
A total of 994 patients took part in the study, 97 of whom were 60 years old or older. They were randomly assigned to either N-AVD or Bv-AVD. The average age of the subgroup aged 60 and over was 66 years, 62% were male and 86% were white. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), event-free survival (EFS), and detailed toxicity assessments.
To view the content you must log in or register.
#standard #care #older #people #advanced